The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | POD1UM-303: retifanlimab and chemotherapy in anal carcinoma
Dominik Modest, MD, Charité – Universitätsmedizin Berlin, Berlin, Germany, discusses the Phase III POD1UM-303 trial (NCT04472429) of retifanlimab, a PD-1 inhibitor, with standard chemotherapy in treatment-naïve patients with locally recurrent/metastatic squamous cell anal carcinoma (SCAC). Adding retifanlimab significantly improved progression-free compared to chemotherapy alone. Retifanlimab also showed a favorable safety profile without disrupting chemotherapy administration, suggesting its potential as a new first-line standard of care for SCAC. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
